On Dec. 25, 2020, orelabrutinib was approved by the China National Medical Products Administration (NMPA) in two indications: the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) /small lymphocytic lymphoma (R/R SLL), and the treatment of patients with R/R MCL. Dr. Jasmine Cui, the co-founder, chairwoman and CEO of InnoCare said, “We are very proud that orelabrutinib was granted BTD after obtaining Orphan Drug Designation.